无防腐剂玻璃体腔注射曲安奈德治疗葡萄膜炎的疗程与长期副作用
该回顾性对比病例系列分析了2012-2014年Cole Eye Institute接受2 mg或4 mg无防腐剂玻璃体腔注射曲安奈德(PF-IVTA)的葡萄膜炎患者,共214眼514次注射,平均随访1.5年。结果显示两种剂量治疗失败时间无统计学显著差异,但接受4+2 mg方案的眼青光眼滤过手术和白内障手术发生率更高,且青光眼手术时间更短。
要点
- 2 mg PF-IVTA治疗持续时间不劣于4 mg PF-IVTA。
- 4+2 mg方案青光眼滤过手术和白内障手术发生率更高。
- 4+2 mg方案青光眼手术时间较2 mg单用更短。
核心结论
- 2 mg PF-IVTA治疗持续时间不劣于4 mg PF-IVTA,且白内障发生和青光眼滤过手术的副作用可能显著更低。
研究设计与样本
- 回顾性、对比性连续病例系列,纳入2012-2014年Cole Eye Institute接受PF-IVTA(2 mg或4 mg)的全部患者,共214眼514次注射,平均随访1.5年。
主要发现
- 接受2 mg PF-IVTA单药与接受4+2 mg PF-IVTA联合方案的眼在人口学分布上相似。
- 两种注射剂量间治疗失败时间(TTF)无统计学显著差异。
- 接受4+2 mg PF-IVTA的眼较2 mg单药眼青光眼滤过手术和白内障手术发生率更高,且青光眼手术时间更短。
临床怎么用
- 对于葡萄膜炎的玻璃体腔曲安奈德治疗,2 mg PF-IVTA可作为与4 mg方案治疗持续时间相当的选项,且可能减少白内障和青光眼手术风险。
局限性
- 回顾性研究设计可能引入选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Noninfectious uveitis has been treated historically with corticosteroid therapy in varying doses and routes. Triesence, a preservative-free sterile formulation of triamcinolone acetonide, has been used in a wide spectrum of ocular pathologies, but there have been few large studies validating its dosing or detailing long-term side effects in uveitic disease. The primary aim of this study was to describe the relative duration of action and side effects of 2 doses of preservative-free intravitreal triamcinolone acetonide (PF-IVTA) in uveitis. DESIGN: Retrospective, comparative consecutive case series. METHODS: Charts of all patients receiving PF-IVTA (2 mg or 4 mg) in a defined time period (2012-2014) at the Cole Eye Institute were examined for patient demographics, time to treatment failure (TTF), use of systemic immunosuppression, use of intraocular pressure-lowering therapies, date of cataract surgery and glaucoma filtration surgery, and adverse events. RESULTS: The final data set examined 514 injections in 214 eyes. Mean duration of follow-up was 1.5 years. There was similar demographic distribution between eyes that received 2 mg PF-IVTA only and eyes that received a combination of 4 + 2 mg PF-IVTA. No statistically significant difference in TTF between injection dosages was observed. There was a higher incidence of glaucoma filtering surgery and cataract surgery in eyes that received 4 + 2 mg PF-IVTA as well as a shorter time to glaucoma surgery, when compared to eyes that received 2 mg PF-IVTA alone. CONCLUSIONS: This retrospective study supports that 2 mg PF-IVTA displayed noninferior treatment duration to 4 mg PF-IVTA, and may carry a significantly lower side-effect profile of cataract development and glaucoma filtering surgery.
引用
- Ganapathy PS, Lowder CY, Arepalli S, et al. Treatment Duration and Side Effect Profile of Long-Term Use of Intravitreal Preservative-Free Triamcinolone Acetonide in Uveitis. Am J Ophthalmol. 2018. PMID: 30053470. doi:10.1016/j.ajo.2018.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。